Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
METHODS: A total of 307 PSRs were reviewed by the UWCCC during this time period. Forty-one were specifically submitted and approved for patients with leukemia or MM. Reason for PSR, status at initiation, previous transplant, and days of hospitalization after PSR and 1 year survival were calculated.
Diagnosis |
Number |
Status at time of PSR |
Previous Transplant |
Median No previous regimens |
Reason for PSR submission |
PSR Regimen |
Mean Survival After PSR starts |
1 yr. survival |
AML, relapsed
|
8 |
Refractory relapse |
88% |
3 |
No SOC1 |
Various |
236d (range 88-575d) |
12% |
AML, other |
2 |
Remission |
0 |
1 |
Nonstandard Transplant regimen |
Transplant regimen |
533 d |
100% |
CML, relapsed |
2 |
Refractory |
No |
3 |
Failed all previous regimens |
Transplant regimen |
289d |
50% |
ALL, newly diagnosed |
5 |
Untreated |
NA |
0 |
Adult treated on pediatric regimen (n=3); elderly (n=2) |
Various |
551d (range 365-981d) |
100% |
ALL, relapsed |
5 |
Relapsed |
20% |
3 (range 1-8) |
No SOC1 |
CVP2, TKI3 based;, BFM4 |
408d (range 167-735d) |
40% |
MM |
15 |
Relapsed, refractory (n=15) 100% |
73% (auto) |
7 (range 2-10) |
Not core regimen (n=13) Rare subtype(n=2) |
PCP5 (n=3); CRD6 (n-4) other |
272 d ( range 74-661) |
60% |
APL |
4 |
untreated |
N/A |
N/A |
Not Core Regimen |
ATRA/Arsenic, other |
788d (range 692-910d) |
100% |
1 SOC; 2 cyclophosphamide, vincristine prednisone; 3 tyrosine kinase inhibitor; 4 Berlin/Frankfurt/Munich; 5Pomalidomide, cyclophosphamide, prednisone; 6carfilzomib, lenalidomide dexamethasone
RESULTS: A total of 41 PSRs were examined. The most common reasons for submission of the PSR was request for a non-core regimen including a recently FDA approved use of an agent (n= 11); no current SOC established (n=13); salvage therapy with older regimen ((n=2). Median 1 yr. survival varied from 12% to 100% depending on diagnosis. Not surprisingly, APL pts displayed the best overall survival, followed by AML, transplanted with a nonstandard conditioning regimen. AML patients relapsing after previous allogeneic transplant had the worst survival, regardless of salvage regimen; only 1 pt. survived longer than 6 months. The median length of hospital stay in these patients following start of PSR was 43 d (range 14-54). Relapsed ALL pts also fared poorly, with 1 year survival of 40% and median days of hospitalization after PSR of 48d (range 0-117). Relapsed refractory MM pts had a variable outcome, with some pts surviving more than 3 years and others for only several months.
CONCLUSION: Use of peer reviewed PSRs resulted in reasonable outcomes in most patients with leukemia and myeloma. However, pts with AML relapsing after allogeneic transplant and those with relapsed ALL fared particularly poorly despite treatment with a peer reviewed treatment plan, presumably chosen for best outcome. Furthermore, these salvage treatments were associated with lengthy hospital stays. Such patients are unlikely to benefit from any currently available regimens and may be more appropriately considered for clinical trials or supportive/ palliative care at time of relapse.
Disclosures: No relevant conflicts of interest to declare.
See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts
*signifies non-member of ASH